The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.

Debrisoquine is an antihypertensive drug that is metabolized by cytochrome P4502D6. Deficient metabolism is inherited as an autosomal recessive condition. We previously reported in a case-control study that extensive metabolizers of debrisoquine were at greater risk of lung cancer compared to poor a...

Descripción completa

Detalles Bibliográficos
Autores principales: Caporaso, N E, Shields, P G, Landi, M T, Shaw, G L, Tucker, M A, Hoover, R, Sugimura, H, Weston, A, Harris, C C
Formato: Texto
Lenguaje:English
Publicado: 1992
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1519603/
https://www.ncbi.nlm.nih.gov/pubmed/1362537

Ejemplares similares

Ejemplares similares